Ziftomenib
4-methyl-5-[[4-[[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1-[(2S)-2-(4-methylsulfonylpiperazin-1-yl)propyl]indole-2-carbonitrile
Molecular Identity
Ziftomenib
4-methyl-5-[[4-[[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1-[(2S)-2-(4-methylsulfonylpiperazin-1-yl)propyl]indole-2-carbonitrile
PubChem CID: 138497449
2D Structure
Properties
C33H42F3N9O2S2
Molecular Formula
717.90
Molecular Weight
g/mol
717.2855
Exact Mass
Da
5.6
XLogP
Above Lipinski threshold
159
TPSA
May have limited oral absorption
2
H-Bond Donors
14
H-Bond Acceptors
1270
Complexity
SMILES
Canonical SMILES
SMILES: CC1=C(C=CC2=C1C=C(N2CC(C)N3CCN(CC3)S(=O)(=O)C)C#N)CN4CCC(CC4)NC5=C6C=C(SC6=NC(=N5)NC)CC(F)(F)FIsomeric SMILES
SMILES: CC1=C(C=CC2=C1C=C(N2C[C@H](C)N3CCN(CC3)S(=O)(=O)C)C#N)CN4CCC(CC4)NC5=C6C=C(SC6=NC(=N5)NC)CC(F)(F)FSynonyms(20)
ziftomenibKO-539UNII-4MOD1F4ENC4MOD1F4ENCKo 539ZIFTOMENIB [INN]4-methyl-5-[[4-[[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1-[(2S)-2-(4-methylsulfonylpiperazin-1-yl)propyl]indole-2-carbonitrilecompound 151 [US10781218B2]Menin-Mixed Lineage Leukemia Protein-Protein Interaction Inhibitor KO 539compound 151 (US10781218B2)1H-INDOLE-2-CARBONITRILE, 4-METHYL-5-((4-((2-(METHYLAMINO)-6-(2,2,2-TRIFLUOROETHYL)THIENO(2,3-D)PYRIMIDIN-4-YL)AMINO)-1-PIPERIDINYL)METHYL)-1-((2S)-2-(4-(METHYLSULFONYL)-1-PIPERAZINYL)PROPYL)-1H-Indole-2-carbonitrile, 4-methyl-5-[[4-[[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]-1-piperidinyl]methyl]-1-[(2S)-2-[4-(methylsulfonyl)-1-piperazinyl]propyl]-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-((2S)-2-(4-methylsulfonylpiperazin-1-yl)propyl)indole-2-carbonitrileRefChem:195960Menin-MLL Inhibitor KO-539
Data from PubChem (NCBI)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Drug Network
Trials and conditions connected to Ziftomenib
Loading drug network...